Hints and tips:
Related Special Reports
...Bristol Myers Squibb is working on contingency plans to “protect the continuity of supply” of medicine in preparation for draft US legislation seeking to restrict Chinese pharmaceutical companies over national...
...Myers Squibb Q1, Capital One Q1, Caterpillar Q1, Comcast Q1, Dassault Systemes Q1, Delivery Hero Q1 trading update, Deutsche Bank Q1, Dow Q1, Drax Group AGM and trading update, Inchcape Q1, Intel Q1, London...
...Myers Squibb Q4, Charter Communications Q4, Chevron Q4, Cigna Group Q4, Danske Bank Q4, Deutsche Bank FY, Electrolux Q4, ExxonMobil Q4, Ferrari Q4, Japan Airlines Q3, KDDI Q3, Mitsui & Co Q3, Panasonic...
...Initial Irish investments by Pfizer and Bristol Myers Squibb more than a half century ago encouraged other multinationals to follow, he said....
...Myers Squibb Q3, Capital One Q3, Comcast Q3, Danone Q3, Ford Motor Company Q3, Fujitsu H1, Harley-Davidson Q3, Hasbro Q3, Heathrow Q3, HelloFresh Q3, Hershey Q3, SK Hynix Q3, Inchcape Q3 trading statement...
...Myers Squibb Q2, Britvic Q3 trading statement, BT Group Q1 trading update, Groupe Casino H1, Centrica H1, CMC Markets Q1 trading update, Comcast Q2, CVS Group trading update, EDF H1, Elementis H1, Ford...
...Sanofi and Bristol Myers Squibb are among those that have struck partnerships with AI-focused start-ups but an acquisition is unusual....
...Myers Squibb Q4, BT Group Q3 trading update, Canada Goose Q3, Chubb Q4, ConocoPhillips Q4, Danske Bank Q4, Dassault Systemes Q4, Deutsche Bank FY, Electrolux FY, Eli Lilly & Co Q4, Estee Lauder Q2, Fast...
...David Elkins, chief financial officer at Bristol-Myers Squibb, says the company remained optimistic about adding to its drug pipeline and did not see a big change in the regulatory environment....
...US, Federal Open Market Committee makes interest rate announcement with officials signalling a 75 basis point rise Results: Airbus H1, BASF Q2, Boeing Q2, Breedon H1, Bristol Myers Squibb Q2, British...
...production index Germany, monthly factory order figures Eurozone, France, Germany, UK: IHS Markit construction PMI data US, monthly motor vehicle sales, payrolls and unemployment figures Results: Aon Q4, Bristol-Myers...
...The chief executive of Bristol-Myers Squibb described the US government’s support for waiver as “very concerning” during an interview at the FT US Pharma and Biotech Summit on Thursday....
...Fresnillo; Lloyds Banking Group; London Stock Exchange; Metro Bank; Nichols; Persimmon; Reckitt Benckiser; WPP; French Connection; J Sainsbury Thursday Altria; Amazon; American Tower; Baxter International; Bristol-Myers...
...He said the company was working on other opportunities with Novartis and also with Bristol-Myers Squibb. “We believe long-term BMS will be as important to us as Novartis has been,” he added....
...That new site will also be used by Juno Therapeutics, a subsidiary of Bristol-Myers Squibb, with which the group signed a deal in March....
...PD-1 inhibitors include Keytruda (Merck of the US) and Opdivo (Bristol-Myers Squibb), while PD-L1 inhibitors include Tecentriq (Roche) and Imfinzi (AstraZeneca)....
...Daclatasvir used to be manufactured by Bristol-Myers-Squibb but the American company no longer makes it....
...According to SEC filings, Elon Musk’s company is the $60bn hedge fund’s second largest holding, behind Bristol-Myers Squibb....
...Indeed, AbbVie’s tilt at Allergan is the latest in a wave of blockbuster pharma deals this year that Bristol-Myers Squibb kicked off in January with a $74bn bid for Celgene....
...Bristol-Myers Squibb agreed to acquire Celgene in a $90bn deal early in January and it was followed by Eli Lilly’s $8bn takeover of Loxo Oncology....
...Lex reckons the purchase of Celgene by Bristol-Myers Squibb for an enterprise value of $90bn could do that....
...Bristol-Myers Squibb’s largest institutional investor has said it will not back the company’s $90bn takeover of Celgene....
...More than 15 imported drugs have been approved this year, including Bristol-Myers Squibb’s Opdivo in June, Merck’s Keytruda last month and Roche’s Alecensa this month, all part of a generation of immunotherapy...
...Merck’s decision to test its drug in combination with chemotherapy will help it open a lead over Bristol-Myers Squibb, its closest rival in the field of immunotherapy....
...For the past year or so, a common talking point among dealmakers was when rather than if Pfizer would make a move on Bristol-Myers Squibb — but that speculation has died down in the past few months....
International Edition